

# 16<sup>th</sup> World Congress on Cancers of the Skin®

## 12<sup>th</sup> Congress of the European Association of Dermato-Oncology

AUGUST 31–SEPTEMBER 3, 2016

VIENNA, AUSTRIA



### Thursday, September 1, 2016

Time	Festsaal	Zeremoniensaal	Rittersaal	Geheime Ratstube
8:00 AM - 8:55 AM	<b>SY4</b> <b>Genetic Testing in Skin Cancer – Methods and Strategies</b> <i>Chairs: J. Malveyh (Barcelona, Spain) M. C. Fargnoli (L'Aquila, Italy)</i>	<b>SY5</b> <b>Cutaneous Lymphoma I Biology, Epidemiology, Genetic, Research</b> <i>Chairs: J. Scarisbrick (Birmingham, UK)</i>	<b>SY6</b> <b>Skin Cancer Centers– What is the Worldwide Standard?</b> <i>Chairs: A.-M. Forsea (Bucharest, Romania) P. Mohr (Buxtehude, Germany)</i>	<b>SY7</b> <b>Basics of (Cutaneous) Immunology</b> <i>Chairs: W. Weninger (Sidney, Australia) S. Grabbe (Mainz, Germany)</i>
	<b>SY4-1</b> 8:00 AM Genetic testing in skin cancer - from specific to abundant G. McArthur (Melbourne, Australia)	<b>SY5-1</b> 8:00 AM Pathogenetic concepts in T-cell lymphoma 2016 S. Withaker (London, UK)	<b>SY6-1</b> 8:00 AM What should an ideal skin cancer center look like? P. Mohr (Buxtehude, Germany)	<b>SY7-1</b> 8:00 AM Principles of cutaneous immunology S. Grabbe (Mainz, Germany)
		<b>SY5-2</b> 8:13 AM Sezary Syndrom and the EORTC translational research projects 2016 M. H. Vermeer (Leiden, Netherlands)	<b>SY6-2</b> 8:15 AM What can we achieve in the light of current limitations? A.-M. Forsea (Bucharest, Romania)	
	<b>SY4-2</b> 8:25 AM Genetic testing in daily practice – what's feasible? M. C. Fargnoli (L'Aquila, Italy)	<b>SY5-3</b> 8:26 AM Results of the cutaneous lymphoma prognostic study (CLIP1) J. J. Scarisbrick (Birmingham, UK)	<b>SY6-3</b> 8:30 AM How can interdisciplinary cooperation maximize our patients benefit? S. Agarwala (Bethlehem, USA)	<b>SY7-2</b> 8:25 AM Trafficking of immune cells in the skin, implications for therapy W. Weninger (Sidney, Australia)
	<b>SY4-3</b> 8:40 AM Genetic testing for skin cancer susceptibility I. Okamoto (Vienna, Austria)	<b>SY5-4</b> 8:39 AM The new WHO 2015 classification of cutaneous lymphomas R. Willemze (Leiden, Netherlands)	<b>SY6-5</b> 8:45 AM <i>Panel Discussion</i> What do we have to do to maximize patient benefit and research output in skin cancer centers?	<b>SY7-3</b> 8:40 AM The emerging role of resident memory T cells in protective immunity and inflammatory disease T. Kupper (Boston, USA)
9:00 AM – 9:30 AM	<b>Coffee Break</b>			<b>SAT3</b> <b>Leo-Pharma Breakfast Symposium More than Meets the Eye - Treating Actinic Keratosis (AK) and beyond</b> <i>Chair: C. Garbe (Tuebingen, Germany)</i>
9:30 AM - 10:00 AM	<b>SY8</b> <b>Melanoma Therapy Drugs and Trials Current Status I – Kinase Inhibitors</b> <i>Chairs: J. J. Grob (Marseille, France) A. Hauschild (Kiel, Germany)</i>	<b>SY10</b> <b>BCC Epidemiology, Biology, Genetics, Clinical Data</b> <i>Chairs: H. Hahn (Tuebingen, Germany) R. Kunstfeld (Vienna, Austria)</i>	<b>SY9</b> <b>Surgery of Skin Cancer Primaries</b> <i>Chairs: F. Roka (Vienna, Austria) R. Kaufmann (Frankfurt, Germany)</i>	9:00 AM Welcome and introduction C. Garbe (Tuebingen, Germany)
	<b>SY8-1</b> 9:30 AM Vem/Cobimetinib G. McArthur (Melbourne, Australia)	<b>SY10-1</b> 09:30 AM Man's most common tumor – the BCC epidemic A. Stratigos (Athens, Greece)	<b>SY9-1</b> 9:30 AM Current standards for the management of primary skin cancer lesions in Europe R. Kaufmann (Frankfurt, Germany)	<b>SAT3-1</b> 9:15 AM What lies beneath? Optimising diagnosis of field cancerisation I. Zalaudek (Graz, Austria)
	<b>SY8-2</b> 9:47 AM Dabrafenib/Trametinib A. Hauschild (Kiel, Germany)	<b>SY10-2</b> 09:50 AM Gorlin-goltz syndrom H. Hahn (Tuebingen, Germany)	<b>SY9-2</b> 9:50 AM Current standards for the management of primary skin cancer lesions in the US J. Gershenwald (Houston, USA)	<b>SAT3-2</b> 9:30 AM AK and beyond: Tailored therapy to optimise patient outcomes J. J. Grob (Marseille, France)
				<b>SAT3-3</b> 9:45 AM Panel discussion
				9:55 AM Closing remarks and wrap up C. Garbe (Tuebingen, Germany)
10:00 AM-10:55 AM	<b>SY8-3</b> 10:04 AM Kinase inhibitors for N-ras mutated patients	<b>SY10-3</b> 10:10 AM Which open questions in BCC biology will we have to answer in the future?		<b>SY11</b> <b>Skin Cancer Biology</b>

		J. J. Grob (Marseille, France)		A. Sekulic (Phoenix, USA)	<b>SY9-3</b> 10:10 AM	The role of mohs surgery in the management of primary skin cancer lesions J. Alcalay (Tel Aviv, Israel)	<i>Chairs:</i> <i>V. Paulitschke (Zuerich, Switzerland)</i> <i>D. Schramek (Toronto, Canada)</i>	
	<b>SY8-4</b> 10:21 AM	Kinase inhibitors for rare mutation subgroups D. Schadendorf (Essen, Germany)	<b>SY10-4</b> 10:25 AM	Use of vismodegib in the real world: analysis of a US insurance claims database C. Sima (San Francisco, USA)	<b>SY9-4</b> 10:30 AM	Management of primary lesions of rare skin tumors F. Roka (Vienna, Austria)	10:00 AM The role of ETS transcription factors in SCC development D. Schramek (Toronto, Canada)	
	<b>SY8-5</b> 10:38 AM	Identification of prognostic subgroups for overall survival in patients (pts) with BRAFV600-mutated metastatic melanoma treated with vemurafenib ± cobimetinib: a pooled exploratory analysis of the BRIM-2, BRIM-3, BRIM-7, and coBRIM studies A. Hauschild (Kiel, Germany)	<b>SY10-5</b> 10:40 AM	Investigator-assessed efficacy and safety of Sonidegib in patients with locally advanced Basal Cell Carcinoma and Metastatic Basal Cell Carcinoma: Results of the BOLT 30-month analysis R. Dummer (Zuerich, Switzerland)			10:20 AM Defining the mode of melanoma heterogeneity and drug sensitivity by real-time cell cycle imaging N. Haass (Queensland, Australia)	
							10:40 AM Proteomics to reveal resistance mechanisms beyond genetic changes V. Paulitschke (Zuerich, Switzerland)	
<b>11:00 AM – 12:00 AM</b>	<b>PL2</b>	<b>Plenary Genetics</b> <i>Chairs:</i> <i>A. Halpern (New York, USA)</i> <i>C. Garbe (Tuebingen, Germany)</i>						
	<b>PL2-1</b> 11:00 AM	Genetics of Nevi – what do they tell us about melanoma? B. Bastian (San Francisco, USA)						
	<b>PL2-2</b> 11:30 AM	Mutanome specific personalized vaccination U. Sahin (Mainz, Germany)						
<b>12:00 AM – 1:00 PM</b>	<b>Lunch Break</b>							
<b>12:15 PM – 1:15 PM</b>			<b>SAT4</b>	<b>AMGEN Lunch Symposium</b> <i>Chair:</i> <i>H. Pehamberger (Vienna, Austria)</i>				
			12:15 PM	Welcome and introduction H. Pehamberger (Vienna, Austria)				
			<b>SAT4-1</b> 12:20 PM	Arming the immune response to target the tumor C. Hoeller (Vienna, Austria)				
			<b>SAT4-2</b> 12:40 PM	Talimogene laherparepvec in clinical practice O. Michielin (Geneva, Switzerland)				
			1:00 PM	Summary and close				
<b>1:30 PM - 2:50 PM</b>	<b>SY12</b>	<b>Melanoma Therapy Drugs and Trials Current Status II – Immunotherapy</b> <i>Chairs:</i> <i>B. Dreno (Nantes, France)</i> <i>J. Weber (Tampa, USA)</i>	<b>SY13</b>	<b>Squamous Cell Carcinoma/AK - Epidemiology, Biology, Local Therapies</b> <i>Chairs:</i> <i>A. Handysuria (Vienna, Austria)</i> <i>G. Hofbauer (Zuerich, Switzerland)</i>	<b>SY14</b>	<b>Open Questions in Dermatopathology of Cutaneous Tumors</b> <i>Chairs:</i> <i>M. C. Mihm (Boston, USA)</i>	<b>SY15</b>	<b>Setinel Node Surgery</b> <i>Chairs:</i> <i>A. Testori (Milano, Italy)</i> <i>M. Gnant (Vienna, Austria)</i>
	<b>SY12-1</b> 1:30 PM	PD-1 R. Dummer (Zuerich, Switzerland)	<b>SY13-1</b> 1:30 PM	From UV to SCC – insights into the biology of field cancerization E. Stockfleth (Bochum, Germany)	<b>SY14-1</b> 1:30 PM	Open questions in the histopathology of cutaneous tumors 2016 M. C. Mihm (Boston, USA)	<b>SY15-1</b> 1:30 PM	Sentinel node in melanoma – the evidence behind the method M. Ross (Houston, USA)
	<b>SY12-2</b> 1:50 PM	Vaccines and cell based therapies B. Dreno (Nantes, France)	<b>SY13-2</b> 1:45 PM	Beyond UV – viral carcinogenesis in SCC A. Handysuria (Vienna, Austria)	<b>SY14-2</b> 1:55 PM	Desmoplastic melanoma K. J. Busam (New York, USA)	<b>SY15-2</b> 1:50 PM	Lessons learned from sentinel node in breast cancer M. Gnant (Vienna, Austria)
	<b>SY12-3</b> 2:10 PM	Novel immunotherapies and combinations J. Weber (Tampa, USA)	<b>SY13-3</b> 2:00 PM	Topical therapy of NMSC R. Kunstfeld (Vienna, Austria)	<b>SY14-3</b> 2:13 PM	TBA R. L. Barnhill (Paris, France)	<b>SY15-3</b> 2:10 PM	Do we need to perform CLND after sentinel? C. Garbe (Tuebingen, Germany)
	<b>SY12-4</b> 2:30 PM	Efficacy and quality of life outcomes in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase III trial (CheckMate 067) D. Schadendorf (Essen, Germany)	<b>SY13-4</b> 2:20 PM	Outcome evaluation of local therapies – which endpoints show the real effect? G. Hofbauer (Zuerich, Switzerland)			<b>SY15-4</b> 2:30 PM	Sentinel node in skin cancer beyond melanoma J. Gershenwald (Houston, USA)
			<b>SY13-5</b>		<b>SY14-4</b> 2:31 PM	Open questions and standards in the pathology of cutaneous SCC A. Sober (Boston, USA)		

	<b>SY12-5</b> 2:40 PM	Patterns of clinical response in talimogene laherparepvec (T-VEC) treated patients with stage IIIB-IVM1a melanoma in the OPTiM phase III trial K. Harrington (London, UK)	2:35 PM	Structured expert consensus on actinic keratosis: an up-to-date treatment algorithm P. Calzavara-Pinton (Brescia, Italy)			
<b>3:00 PM - 4:00 PM</b>	<b>SAT5</b>	<b>F. Hoffmann - La Roche Ltd.</b> <b>Vienna Coffeehouse Symposium</b> <b>Melanoma: Treat it Personally.</b> <b>Optimising Outcomes With Targeted Therapies in Advanced Melanoma in Your Clinical Practice</b>  <i>Chair: J. Larkin (London, UK)</i>	<b>Coffee Break</b>				
	<b>SAT5-1</b> 3:00 PM	Setting the scene: the current standards of care in advanced melanoma J. Larkin (London, UK)					
	<b>SAT5-2</b> 3:15 PM	Improving outcomes for patients: interactive metastatic melanoma case series J. Larkin (London, UK) C. Robert (Paris, France) R. Dummer (Zuerich, Switzerland)					
	<b>SAT5-3</b> 3:30 PM	Perspectives: expert panel discussion J. Larkin (London, UK) C. Robert (Paris, France) R. Dummer (Zuerich, Switzerland)					
	3:45 PM	<i>Melanoma summary and close</i> J. Larkin (London, UK)					
<b>4:15 PM - 5:15 PM</b>	<b>PL3</b>	<b>Plenary Melanoma</b>  <i>Chairs: D. Schadendorf (Essen, Germany) G. McArthur (Brisbane, Australia)</i>					
	<b>PL3-1</b> 4:15 PM	Combination therapies for skin cancer – where do we go? C. Blank (Amsterdam, Netherland)					
	<b>PL3-2</b> 4:45 PM	Biomarkers for melanoma treatment – how will they impact our treatment decisions? O. Michelin (Lausanne, Switzerland)					
<b>5:20 PM - 6:20 PM</b>	<b>SY16</b>	<b>Controversies: Is Immunotherapy the Current Standard for Every Melanoma Patient? Pro/Con</b> <i>Chairs: R. Dummer (Zuerich, Switzerland) P. Arenberger (Prague, Czech Republic)</i>	<b>SY17</b>	<b>PDT</b>  <i>Chairs: S. Radakovic (Vienna, Austria) R.-M. Szeimis (Recklinghausen, Germany)</i>	<b>SY18</b>	<b>Vaccines for Cutaneous Tumors</b>  <i>Chairs: U. Sahin (Mainz, Germany) G. Schuler (Erlangen, Germany)</i>	
	<b>SY16-1</b> 5:20 PM	Pro J. Larkin (London, UK)	<b>SY17-1</b> 5:20 PM	Topical photodynamic therapy in dermatology – how does it work? L. Braathen (Bern, Switzerland)	<b>SY18-1</b> 5:20 PM	Vaccines for melanoma - time for a comeback? G. Schuller (Erlangen, Germany)	
	<b>SY16-2</b> 5:40 PM	Contra O. Michielin (Lausanne, Switzerland)	<b>SY17-2</b> 5:35 PM	PDT for skin cancer - what should we treat and what not? E. Sotiriou (Thessaloniki, Greece)	<b>SY18-2</b> 5:40 PM	Oncolytic viruses: vehicles for endogenous vaccination? R. Andtbacka (Salt Lake City, USA)	
	6:00 PM	Discussion with the audience	<b>SY17-3</b> 5:50 PM	Day - light PDT - a major breakthrough in dermatological PDT? R.-M. Szeimis (Recklinghausen, Germany)	<b>SY18-2</b> 5:40 PM	Oncolytic viruses: vehicles for endogenous vaccination? R. Andtbacka (Salt Lake City, USA)	
			<b>SY17-4</b> 6:05 PM	PDT - associated pain - are there means for relief? S. Radakovic (Vienna, Austria)	<b>SY18-3</b> 6:00 PM	RNA based melanoma specific vaccines – a true personalized therapy U. Sahin (Mainz, Germany)	